Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
暂无分享，去创建一个
E. Raymond | J. Schellens | A. Italiano | A. Schueler | R. Kefford | C. Lebbé | S. Faivre | A. Awada | S. Leijen | N. Houédé | S. Rottey | S. Goodstal | J. Delord | C. Gomez-Roca | T. Lesimple | P. Aftimos | V. Kruse | G. Massimini | M. Dinulescu | Celine Pages